Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04806295

The Leukemia and Lymphoma Society (LLS) National Research Registry

The Leukemia and Lymphoma Society (LLS) has built a National Research Registry to evaluate real world experiences and medical outcomes for people with blood cancer, before, during, and after blood cancer treatments.

Recruiting

Interested in participating?

Request Info

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

The LLS National Research Registry is a real-world experiences and outcomes research registry; a collection of patient information and medical data, over time, about people who have a particular disease or condition, or who receive a particular treatment.

The LLS National Research Registry Protocol will:

  • Answer research questions using data collected from people with blood cancers. Such research involves analyses of subject profile information completed by subjects and medical records data.
  • Obtain permission from LLS National Research Registry research subjects to have Ciitizen, a third-party engaged by LLS, act as their proxy to retrieve full medical record data including images at no cost to research subjects. Note: Patient can choose to upload their medical records into their account, directly.
  • Obtain permission from LLS National Research Registry research subjects to share summary data with research partners (like academic researchers, advocacy groups, and pharmaceutical companies) that are advancing treatments for blood cancer. "Summary data" represents the important elements of medical record data, coded for research use, with personal identifiers like name, address, and phone number removed.
  • Obtain permission from LLS National Research Registry research subjects to be contacted from time to time, for them to provide updated medical information.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

People with blood cancer, before, during, and after blood cancer treatments.

Exclusion criteria

People unable or unwilling to sign informed consent.

Treatment and study plan

any/all treatments for blood cancer

Other

Following people undergoing any/all treatments for blood cancer.

Primary outcomes

  1. LLS will monitor outcomes of people being treated for blood cancer.

    Time frame: 10 years

    . The LLS National Research Registry will collect data on up to 1000 research subjects, over up to 10 years, storing that data, including protected health information (PHI) and images, in secure databases, and share de-identified summary data with research partners (like academic researchers, advocacy groups, and pharmaceutical companies) that are advancing treatments for blood cancer. Participation in The LLS National Research Registry may not give research subjects any immediate benefit. It is hoped the knowledge gained from data collected in The LLS National Research Registry will benefit people with blood cancers in the future using this information for research purposes, directed at blood cancers and associated comorbidities.

Study contacts

Contact information is provided by the study sponsor or research team.

Brian J Chadwick, BS RN

CONTACT

[email protected]

9144145788

Larry Saltzman, MD

CONTACT

[email protected]

844-696-7228

Sponsors and collaborators

Lead sponsor

Blood Cancer United

Other

Registry information

Important dates

Study start
2017
Primary completion
2027
Study completion
2027
First posted
Mar 19, 2021
Registry last updated
Apr 7, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.